OTCMKTS:ABSCF AB Science (ABSCF) Stock Price, News & Analysis $2.70 0.00 (0.00%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$2.70▼$2.7050-Day Range$2.70▼$2.7052-Week Range$2.55▼$3.84VolumeN/AAverage Volume39,925 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get AB Science alerts: Email Address Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About AB Science Stock (OTCMKTS:ABSCF)AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.Read More ABSCF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABSCF Stock News HeadlinesJune 30, 2024 | americanbankingnews.comShort Interest in AB Science S.A. (OTCMKTS:ABSCF) Grows By 27.2%May 29, 2024 | finance.yahoo.comAB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJuly 4, 2024 | Paradigm Press (Ad)Biden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.May 13, 2024 | finance.yahoo.comAB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036May 7, 2024 | finance.yahoo.comAB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientMay 7, 2024 | yahoo.com7 Best Ab Exercises That Can Help With Fat Loss By Summer, According To Trainers: Planks & MoreMay 2, 2024 | finance.yahoo.comAB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceApril 30, 2024 | finance.yahoo.comAB Science announces a slight delay in the publication of its 2023 annual financial reportJuly 4, 2024 | Paradigm Press (Ad)Biden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.April 23, 2024 | morningstar.comAB Science ABSCFApril 18, 2024 | markets.businessinsider.comAskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failureApril 4, 2024 | msn.comBrandon student off to science fair finalsApril 3, 2024 | finance.yahoo.comAB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSMarch 13, 2024 | finance.yahoo.comAB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseMarch 7, 2024 | finance.yahoo.comAB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science developmentMarch 6, 2024 | finance.yahoo.comAB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the CompanyFebruary 29, 2024 | finance.yahoo.comAB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CETFebruary 26, 2024 | finance.yahoo.comAB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALSFebruary 23, 2024 | msn.comScience Center ranks among Top 5 USA Today's Readers' Choice Awards for 3 consecutive yearsJanuary 26, 2024 | finance.yahoo.comAB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyJanuary 15, 2024 | finance.yahoo.comAB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosisNovember 28, 2023 | finance.yahoo.comAB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell diseaseNovember 27, 2023 | finance.yahoo.comAB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”November 13, 2023 | morningstar.comAB Science ABOctober 31, 2023 | businessinsider.comThe head of AB InBev's entertainment studio has exited in the latest marketing shakeup at the Anheuser-Busch parentSeptember 29, 2023 | finance.yahoo.comAB Science today reports its revenues for the first half of 2023 and provides an update on its activitiesSeptember 25, 2023 | yahoo.comABC Moves Forward With ‘Dancing With the Stars’ Premiere After Considering DelaySee More Headlines Receive ABSCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AB Science and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:ABSCF CUSIPN/A CIKN/A Webwww.ab-science.com Phone(314) 720-0014FaxN/AEmployees89Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Alain Moussy MBACo-Founder, Chairman, President, CEO, MD & Scientific DirectorMr. Laurent Guy MBAChief Financial OfficerMr. Christian FASSOTTEGlobal Chief Medical OfficerMr. Alexis BERNARDHead of Veterinary SalesMr. Harshad KULKARNIHead of StatisticsDr. Albert Ahn D.V.M.President of USA OperationsMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAbacus Health ProductsOTCMKTS:ABAHFAbattis BioceuticalsOTCMKTS:ATTBFView All Competitors ABSCF Stock Analysis - Frequently Asked Questions How have ABSCF shares performed in 2024? AB Science's stock was trading at $2.55 at the beginning of the year. Since then, ABSCF stock has increased by 5.9% and is now trading at $2.70. View the best growth stocks for 2024 here. Are investors shorting AB Science? AB Science saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 33,700 shares, an increase of 27.2% from the May 31st total of 26,500 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days. View AB Science's Short Interest. How do I buy shares of AB Science? Shares of ABSCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ABSCF) was last updated on 7/4/2024 by MarketBeat.com Staff From Our PartnersOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThe End of Privacy for Americans… Get Out of Cash Now!Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.Golden Crest | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I expla...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AB Science S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share AB Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.